Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a post on X:
“Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations (Aug 8, 2024) Takeda et al.”
To which Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, added on X:
“Thanks for revisiting that, Mike!
Indeed, my first real project as an onc fellow was a retrospective review of almost 500 cases of small bowel adenocarcinoma (SBA). An excruciatingly painful experience as much of this was paper chart review but ever since, I have been very interested in small-bowel SBAs. We now have Katrina Pedersen as our in-house expert on the topic. I see potential for KRAS inhibitors in this disease as up to half of them are KRAS mutated.”
Title: A single-institution experience with 491 cases of small bowel adenocarcinoma
Authors: Thorvardur R. Halfdanarson, Robert R. McWilliams, John H. Donohue, J. Fernando Quevedo.
Other articles featuring Thor Halfdanarson and Mike Thompson on OncoDaily.
